Adaptive announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response.
Adaptive announced today that Robert Hershberg, M.D., Ph.D., has joined the company’s board of directors. Dr. Hershberg will work closely with the board and management team to focus on corporate strategy and clinical development.
Luke Timmerman, National Biotech Editor of Xconomy, attended the American Society of Hematology (ASH) meeting in Atlanta, GA, last month, and wrote Adaptive has "emerged on the national stage with valuable new approaches to diagnosis and disease monitoring."
Adaptive today introduced clonoSEQ, a clinical assay to measure minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today’s most common pathology tests. clonoSEQ will be available for widespread clinical use by mid-2013.
Adaptive will be presenting data at the Annual Meeting of the American Society of Hematology 2012 in Atlanta, Georgia, highlighting the clinical utility of next generation sequencing to monitor minimal residual disease (MRD) and to measure immune reconstitution after cord blood transplantation.
Adaptive Biotechnologies Corporation has named respected industry-veteran Ilan “Lanny” Kirsch, M.D. as its new Senior Vice President of Translational Medicine, responsible for leading the development and launch of clinical diagnostic applications stemming from its immunoSEQ and quanTILfy technology platforms.
SEATTLE, WA, September 5, 2012 – Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune... View Article
SEATTLE, WA, September 5, 2012 – A recent study published in The Journal of Immunology details significant discoveries in the... View Article
SEATTLE, WA, August 13, 2012 – Adaptive Biotechnologies Corporation, a leading provider of next-generation sequencing assays for the adaptive immune... View Article
SEATTLE, WA, June 10, 2012 – Chad Robins, co-Founder and CEO of Adaptive Biotechnologies, will speak at the Life Science... View Article
1551 Eastlake Ave E, Suite 200
Seattle WA 98102
(855) 466-8667 (toll free)
© 2013 Copyright. Adaptive Biotechnologies LLC. All rights reserved.